Regenerative Therapies Library
Every article, presentation, spotlight, and news item we've tagged to Regenerative Therapies.
Showing 265–288 of 310
Clonal hematopoiesis boosts response to immune checkpoint therapy
Clonal hematopoiesis—the age-related expansion of mutant blood cell populations—enhances response to immune checkpoint inhibitors in cancer patients. This unexpected finding reframes a hallmark of aging as potentially protective in the context of immunotherapy, with implications for how we interpret immune aging and treatment efficacy.
Gut Bacteria Strain Reverses Age-Related Lung Fibrosis
A Lactobacillus strain (L9) found in centenarians reduces pulmonary fibrosis in aging mice by 30% through a metabolite-signaling pathway that suppresses collagen synthesis. The mechanism operates through the JNK signaling cascade and senescence-associated inflammatory cytokines, establishing a direct gut-to-lung biochemical axis relevant to fibrotic disease prevention.
GLP-1 joint injection shows promise for knee osteoarthritis
4Moving Biotech has enrolled 129 patients in a Phase 2a trial of 4P004, a GLP-1 receptor agonist delivered directly into the knee joint to reduce inflammatory mechanisms in osteoarthritis. The trial will measure pain reduction and synovial tissue changes over 12 weeks, with results expected by end of 2026.
Cellular silencing bypass extends gene therapy durability
Houdini Bio has developed a machine learning platform that redesigns therapeutic DNA to evade the HUSH complex, a cellular mechanism that silences foreign genetic material. This approach extends gene therapy durability while reducing required doses, with particular relevance for neurodegenerative diseases where sustained expression in long-lived neurons is critical to therapeutic outcome.
NB4168 bioavailability edge for rare disease clinical trials
Niagen Bioscience is advancing NB4168, an oral candidate for Ataxia Telangiectasia, through preclinical development with contract partner Evotec. Nonclinical studies show NB4168 achieves substantially higher blood exposure than NR chloride, positioning the compound for IND submission and clinical evaluation.
Myostatin inhibitors preserve muscle mass during GLP-1 weight loss
NorthStrive Biosciences has filed patent applications for two therapeutic candidates designed to preserve lean muscle mass during GLP-1-mediated weight loss and other catabolic states. The compounds target myostatin and activin A pathways through peptide and probiotic delivery mechanisms, addressing a significant gap in current obesity pharmacotherapy where muscle loss accompanies fat loss.
Translation Attenuation Extends Lifespan and Protects Neurons
Atypical tetracyclines extend lifespan and protect neurons from ferroptotic damage by reducing protein synthesis through mechanisms independent of their antibiotic activity. This identifies translation attenuation as a pharmacologically targetable pathway for longevity and neuroprotection across multiple organism models.
Liver Protein Signatures Outpredict Mortality Risk in Aging
Circulating protein signatures enriched in liver and immune markers predict all-cause mortality in older adults with superior performance to conventional clinical risk factors. A 20-protein score achieved C-index 0.81 for mortality discrimination and validated consistently across independent cohorts, establishing plasma proteomics as a scalable biomarker platform for biological age stratification.
Multiomic single-cell perturbation screens reveal critical lncRNA regulators of senescence
A systematic screen of 32 aging-associated long non-coding RNAs identified HOTAIRM1 as a critical regulator of DNA repair pathways, with restoration of HOTAIRM1 in aged mouse lungs reducing fibrosis. This work establishes lncRNA regulation as a targetable mechanism in cellular senescence.
Progeria Research Reveals Cardiovascular Aging Mechanisms
Progeria research has matured to the point where therapeutic strategies are moving from basic science toward clinical implementation. Understanding the molecular mechanisms driving accelerated aging in Hutchinson–Gilbert progeria syndrome offers direct insights into cardiovascular pathology and age-related tissue degeneration in the general population.
FFAR4 Activation Reverses Kidney Senescence in Aging
Omega-3 polyunsaturated fatty acids reduce cellular senescence in kidney tissue through FFAR4 receptor activation, improving filtration function and reducing fibrosis in aging and diseased kidneys. This mechanism explains why previous clinical trials showed inconsistent results and identifies a specific molecular target for renal protection.
Japanese startup makes hair follicle regeneration breakthrough
OrganTech has identified a three-cell configuration—including a previously uncharacterized mesenchymal cell type—capable of regenerating fully functional hair follicles that maintain cycling and production in vivo. This work establishes a cellular blueprint for hair follicle regeneration and suggests broader applications for complex tissue reconstruction.
Liver Regeneration Shifts From Theory to Tissue Reconstruction
Regenerative medicine is advancing from theoretical to practical application in liver repair, with organoid technology and engineered tissues now enabling researchers to reconstruct damaged liver tissue and potentially restore function. This represents a fundamental shift from managing liver decline to actively rebuilding organ structure—a capability with significant implications for extending healthspan in aging populations.
mPGES-2 Links Kidney Aging to Bone Loss
Podocyte-derived mPGES-2 regulates both renal aging and bone loss in aging, establishing a direct mechanistic link between kidney function decline and skeletal deterioration. This finding identifies a specific molecular pathway that coordinates the decline of two major systems involved in longevity and quality of life.
Dopamine neuron replacement emerges as Parkinson's regenerative therapy
Kenai Therapeutics completed enrollment in its Phase 1b/2a REPLACE trial of RNDP-001, an off-the-shelf cell therapy designed to replace dopamine-producing neurons lost to Parkinson's disease rather than merely compensate for their absence. This approach represents a fundamental shift from symptomatic management toward actual neural regeneration, with potential implications for how neurodegenerative diseases are treated.
Immune Tolerance Induction Unlocks Allogeneic Islet Therapy
LyGenesis received funding to develop immune tolerance protocols for pancreatic islet transplantation in type 1 diabetes, leveraging thymic biology to enable allogeneic cell therapy without chronic immunosuppression. This approach addresses a critical barrier in cellular regenerative medicine: preventing immune rejection while restoring endocrine function.
Neural Regeneration Outpaces Dopamine Replacement in Parkinson's
TreeFrog Therapeutics' TFG-001, a 3D neural microtissue therapy, demonstrated accelerated dopamine release and neural reconnection in preclinical Parkinson's models, suggesting a shift from symptomatic treatment toward regenerative restoration of damaged neural architecture. This approach addresses a fundamental longevity challenge: whether neurodegenerative decline can be reversed through structural repair rather than chemical compensation.
Autophagy‐Independent Function of ATG‐18 Is Essential for Gonadal Longevity in Caenorhabditis elegans
ATG-18, a protein long associated with autophagy, extends lifespan through a mechanism independent of autophagy itself when the germline is removed. In the intestine, ATG-18 extends lifespan by interacting with PCK-2, an enzyme involved in glucose production, revealing a tissue-specific, non-autophagic pathway to longevity.
Youthful blood proteins found in Swiss centenarians
The SWISS100 study reveals that centenarians maintain blood protein profiles resembling those of much younger adults, with notably lower oxidative stress and finely balanced metabolic systems. This molecular signature suggests that exceptional longevity correlates with sustained cellular integrity rather than accelerated compensatory mechanisms, offering a model for understanding how aging can be slowed at the fundamental biological level.
SIRT6 Gene Therapy Improves Survival in Aging Dogs
Genflow's SIRT6-targeted gene therapy in aging dogs showed improved survival at three months post-treatment with no adverse events reported. The trial, enrolling 24 beagles over age 10, represents an early-stage assessment of whether genetic interventions can reverse hallmarks of aging in a mammalian model relevant to human longevity research.
Immune-Evasive Insulin Cells Survive Without Suppression
Sana Biotechnology's immune-evasive cell therapy (UP421) has demonstrated survival of transplanted insulin-producing cells without immunosuppressive medication in a first-in-human study, with transplanted cells responding dynamically to glucose levels after 14 months. This approach fundamentally reframes type 1 diabetes treatment from immune suppression to immune tolerance, with potential implications for regenerative medicine across multiple organ systems.
FDA fast-tracks United Therapeutics’ bioengineered liver tech
United Therapeutics' bioengineered liver system, miroliverELAP, has received FDA Regenerative Medicine Advanced Therapy designation, accelerating its development as a bridge therapy for acute liver failure patients. The technology uses a decellularized pig liver scaffold seeded with human cells to provide extracorporeal organ support, potentially improving survival in the 30% of patients ineligible for or unable to access transplantation in time.
Designs for Health launches NeuroCalm Peptide for gut-brain support
Designs for Health introduced NeuroCalm Peptide, combining a milk-derived peptide (Lactium) with a heat-treated Lactobacillus strain to modulate the gut-brain axis. Clinical evidence suggests the formulation may reduce perceived stress and salivary cortisol while supporting sleep quality and emotional resilience through microbiome and nervous system pathways.
Adjustable Gene Therapy Turns Fat Cells Into Controllable Drug Factories
Remedium Bio has secured $10 million in Series A funding to develop adjustable gene therapies that reprogram fat cells to produce therapeutic proteins long-term. The platform's ability to modulate protein expression after treatment addresses a fundamental limitation of traditional gene therapy: the inability to change dosing once administered.